checkAd

     182  0 Kommentare Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting - Seite 3

    Contacts:

    Harpoon Therapeutics, Inc.
    Georgia Erbez
    Chief Financial Officer
    650-443-7400
    media@harpoontx.com

    Lesen Sie auch

    Westwicke ICR
    Robert H. Uhl
    Managing Director
    858-356-5932
    robert.uhl@westwicke.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting - Seite 3 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that the preclinical data on HPN601 for the treatment …